# OPTION-EMEA Clinical Trial

> **NCT07349121** · NA · NOT_YET_RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 500 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)
- Stroke Prevention in Patients With Atrial Fibrillation
- Left Atrial Appendage Closure
- Pulsed Field Ablation
- Atrial Fibrillation Ablation Procedure
- Concomitant Procedures

## Interventions

- **DEVICE:** Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case
- **PROCEDURE:** Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure

## Key facts

- **NCT ID:** NCT07349121
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349121, "OPTION-EMEA Clinical Trial". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07349121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*